Azithromycin concentrations in serum and bronchial secretions of patients with cystic fibrosis

Clinical Drug Investigation

Volumn 21, Issue 5, 2001, Pages 353-360

  Cipolli, Marco ^a   Cazzola, Giantonio ^a   Novelli, Andrea ^b   Cassetta, Maria Iris ^b   Fallani, Stefania ^b   Mazzei, Teresita ^b  

^a UNIVERSITY HOSPITAL OF VERONA   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; CLARITHROMYCIN; ERYTHROMYCIN; ROKITAMYCIN; ROXITHROMYCIN; VIRULENCE FACTOR;

ADULT; ANTIBIOTIC THERAPY; ARTICLE; BRONCHUS SECRETION; CLINICAL ARTICLE; CLINICAL TRIAL; CONCENTRATION RESPONSE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYSTIC FIBROSIS; DOSE RESPONSE; DRUG BLOOD LEVEL; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG INFECTION; MALE; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; RANDOMIZED CONTROLLED TRIAL; TISSUE DISTRIBUTION;

EID: 0035007510     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-200121050-00005     Document Type: Article

References (5)

1. Hoiby N. Cystic fibrosis and endobronchial pseudomonas infection. Curr Opin Pediatr 1993; 5: 247-54
2. Kobayashi H. Biofilm disease: its clinical manifestation and therapeutic possibilities of macrolides. Am J Med 1995; 99 Suppl 6A: 26s-30s.
3. Hoiby N. Diffuse panbronchiolitis and cystic fibrosis: east meets west. Thorax 1994; 49: 531-2
4. Howe RA, Spencer RC. Macrolides for the treatment of Pseudomonas aeruginosa infections? J Antimicrob Chemother 1997; 40: 153-5
5. Ichimiya T, Takeoka K , Hiramatsu K, et al. The influence of . azithromycin on the biofilm formation of Pseudomonas aeruginosa in vitro. Chemotherapy 1996; 42: 186-91